Almac is to launch the Flexyte protease assay platform at the 2010 Society for Biomolecular Sciences (SBS) meeting in Arizona on 11-15 April.
Flexyte protease assays are said to harness the power and potential of fluorescence lifetime technology for robust, efficient and economical screening of proteases.
Avoiding radioactivity, antibodies and associated costs, fluorescence lifetime technology enables homogenous, robust and reliable assays with minimised interference from problem compounds, and will allow miniaturisation and multiplexing, while maintaining an information-rich output.
Flexyte protease assays are based on labelled peptide substrates that have been developed for a variety of proteases.
The generic peptide approach enables Flexyte protease assays to be configured for a range of proteases.
Almac said it will provide a custom assay development service for any protease of interest to customers.
